Phase 2 Study of the Safety, Tolerability and Pilot Efficacy of Oral Factor Xa Inhibitor Betrixaban Compared to Warfarin
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Michael Ezekowitz, MD, PhD,
Lankenau Institute for Medical Research and The Heart Center, United States
Study DirectorKOL profile → - Paul Dorian, MD
University of Toronto, Canada
Study Director - Rafael Diaz, MD
Instituto Cardiovascular de Rosario, Argentina
Study Director - Stefan H. Hohnloser, MD
Johann Wolgang Goethe University, Frankfurt, Germany
Study Director - Stuart Connolly, MD, FRCP
Population Health Research Institute, McMaster University
Study Chair
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
21 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Portola Investigational Site
Longueuil, Quebec, Canada
- Portola Investigational Site
Montreal, Quebec, Canada
- Portola Investigational Site
Anaheim, California, United States
- Portola Investigational Site
Colorado Springs, Colorado, United States
- Portola Investigational Site
Melbourne, Florida, United States
- Portola Investigational Site
Miami, Florida, United States
- Portola Investigational Site
Ormond Beach, Florida, United States
- Portola Investigational Site
Pensacola, Florida, United States
- Portola Investigational Site
Port Charlotte, Florida, United States
- Portola Investigational Site
Aurora, Illinois, United States
- Portola Investigational Site
Auburn, Maine, United States
- Portola Investigational Site
Columbia, Maryland, United States
- Portola Investigational Site
Salisbury, Maryland, United States
- Portola Investigational Site
Towson, Maryland, United States
- Portola Investigational Site
Tupelo, Mississippi, United States
- Portola Investigational Site
St Louis, Missouri, United States
- Portola Investigational Site
Poughkeepsie, New York, United States
- Portola Investigational Site
Hillsboro, Oregon, United States
- Portola Investigational Site
Wynnewood, Pennsylvania, United States
- Portola Investigational Site
Rapid City, South Dakota, United States
- Portola Investigational Site
Norfolk, Virginia, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Oct 2008
- Primary completion
- 31 Aug 2009
- Completion
- 30 Nov 2009
- Last update posted
- 7 Aug 2023
- Registered enrollment
- 508
- Registry id
- NCT00742859
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.